BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32701257)

  • 1. Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.
    Shae D; Baljon JJ; Wehbe M; Christov PP; Becker KW; Kumar A; Suryadevara N; Carson CS; Palmer CR; Knight FC; Joyce S; Wilson JT
    ACS Nano; 2020 Aug; 14(8):9904-9916. PubMed ID: 32701257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
    Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
    J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines.
    Qiu F; Becker KW; Knight FC; Baljon JJ; Sevimli S; Shae D; Gilchuk P; Joyce S; Wilson JT
    Biomaterials; 2018 Nov; 182():82-91. PubMed ID: 30107272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
    Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
    Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy.
    Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G
    Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.
    Castro Eiro MD; Hioki K; Li L; Wilmsen MEP; Kiernan CH; Brouwers-Haspels I; van Meurs M; Zhao M; de Wit H; Grashof DGB; van de Werken HJG; Mueller YM; Schliehe C; Temizoz B; Kobiyama K; Ishii KJ; Katsikis PD
    J Immunol; 2024 Feb; 212(3):455-465. PubMed ID: 38063488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8
    Park KS; Nam J; Son S; Moon JJ
    Biomaterials; 2021 Jul; 274():120844. PubMed ID: 33962217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
    Lu ZD; Chen YF; Shen S; Xu CF; Wang J
    ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-Induced Neoantigen Nanovaccines Enhance Checkpoint Blockade Cancer Immunotherapy.
    Chen G; Li X; Li R; Wu K; Lei Z; Dai R; Roche K; Wang AZ; Min Y
    ACS Nano; 2023 Oct; 17(19):18818-18831. PubMed ID: 37750443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-Based Cancer Vaccine Delivery via the STINGΔTM-cGAMP Complex.
    He Y; Hong C; Fletcher SJ; Berger AG; Sun X; Yang M; Huang S; Belcher AM; Irvine DJ; Li J; Hammond PT
    Adv Healthc Mater; 2022 Aug; 11(15):e2200905. PubMed ID: 35670244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer.
    Zhou L; Hou B; Wang D; Sun F; Song R; Shao Q; Wang H; Yu H; Li Y
    Nano Lett; 2020 Jun; 20(6):4393-4402. PubMed ID: 32459969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programming peptide-oligonucleotide nano-assembly for engineering of neoantigen vaccine with potent immunogenicity.
    Xiang Z; Lu J; Rao S; Fu C; Yao Y; Yi Y; Ming Y; Sun W; Guo W; Chen X
    Theranostics; 2024; 14(6):2290-2303. PubMed ID: 38646651
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
    Perera SA; Kopinja JE; Ma Y; Muise ES; Laskey J; Chakravarthy K; Chen Y; Cui L; Presland J; Sathe M; Javaid S; Minnihan EC; Ferguson HM; Piesvaux J; Pan BS; Zhao S; Sharma SK; Woo HC; Pucci V; Knemeyer I; Cemerski S; Cumming J; Trotter BW; Tse A; Khilnani A; Ranganath S; Long BJ; Bennett DJ; Addona GH
    Mol Cancer Ther; 2022 Feb; 21(2):282-293. PubMed ID: 34815361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.